Holen Sie sich die Stockscreener-App
6.76
4.81%
0.31
Handel nachbörslich:
6.74
-0.02
-0.30%
Schlusskurs vom Vortag:
$6.45
Offen:
$6.44
24-Stunden-Volumen:
1.33M
Relative Volume:
1.38
Marktkapitalisierung:
$539.49M
Einnahmen:
$116.30M
Nettoeinkommen (Verlust:
$17.73M
KGV:
32.19
EPS:
0.21
Netto-Cashflow:
$20.88M
1W Leistung:
+4.32%
1M Leistung:
+4.81%
6M Leistung:
-46.81%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.37
$6.80
1-Wochen-Bereich:
$6.18
$6.80
52-Wochen-Spanne:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Firmenname
Niagen Bioscience Inc
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Vergleichen Sie NAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
6.76 | 514.75M | 116.30M | 17.73M | 20.88M | 0.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
Should I hold or sell Niagen Bioscience Inc. stock in 20252026 world cup usa national team quarterfinals young talents transition play match prediction tactical review - Улправда
Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market (NASDAQ:NAGE) - Seeking Alpha
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
What date does Niagen Bioscience, Inc.'s (NAGE) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Precision Wealth Strategies LLC Makes New $1.53 Million Investment in Niagen Bioscience, Inc. $NAGE - MarketBeat
BSW Wealth Partners Takes Position in Niagen Bioscience, Inc. $NAGE - Defense World
Niagen Bioscience acquires existing nicotinamide riboside patent portfolio - MSN
Niagen Bioscience acquires patent portfolio from Queen’s University Belfast By Investing.com - Investing.com Nigeria
Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast - marketscreener.com
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast - PharmiWeb.com
Niagen Bioscience (NAGE) Secures Key Patents, Boosts Revenue For - GuruFocus
Niagen Bioscience acquires patent portfolio from Queen’s University Belfast - Investing.com
Niagen Bioscience (NAGE) Secures Exclusive Ownership of Key Pate - GuruFocus
Niagen Bioscience Secures Full Ownership of Key NR Patents - TipRanks
Niagen Bioscience secures full ownership of key NR patents - MSN
Niagen Bioscience acquires existing core nicotinamide riboside patent portfolio from Queen's University Belfast - marketscreener.com
Niagen Bioscience Signs Patent Assignment Agreement With Queen's University Belfast - TradingView — Track All Markets
Niagen Bioscience (NAGE) secures full patent rights via new QUB deal - Stock Titan
Niagen Bioscience (STU:OCD1) EV-to-OCF : 19.90 (As of Dec. 22, 2025) - GuruFocus
Niagen Bioscience (STU:OCD1) EV-to-FCF : 20.14 (As of Dec. 22, 2025) - GuruFocus
Niagen Bioscience (FRA:OCD1) EV-to-OCF : 19.90 (As of Dec. 21, 2025) - GuruFocus
Market Outlook: Should I hold or sell Niagen Bioscience Inc. stock in 20252025 EndofYear Setup & Daily Profit Focused Screening - ulpravda.ru
Is Niagen Bioscience Inc. stock a safe buy before earningsWatch List & High Accuracy Buy Signal Tips - Улправда
Why Niagen Bioscience Inc. (OCD1) stock stays undervaluedPortfolio Profit Report & Precise Entry and Exit Recommendations - Улправда
Why Niagen Bioscience Inc. stock could see breakout soonStop Loss & AI Based Trade Execution Alerts - Улправда
Is Niagen Bioscience Inc. stock resilient to inflationJuly 2025 Outlook & Risk Controlled Stock Pick Alerts - Улправда
Trade Report: Is Niagen Bioscience Inc. stock resilient to inflationStop Loss & Weekly High Conviction Trade Ideas - Улправда
Volume Recap: Why Niagen Bioscience Inc. (OCD1) stock stays undervalued2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - Улправда
Can Niagen Bioscience Inc. stock outperform in 2025 bull market2025 Stock Rankings & Smart Allocation Stock Tips - DonanımHaber
Published on: 2025-12-19 14:46:11 - DonanımHaber
Will Niagen Bioscience Inc. stock deliver better than expected guidanceJuly 2025 Short Interest & Expert Curated Trade Setups - Улправда
Is Niagen Bioscience Inc. stock vulnerable to regulatory risksQuarterly Investment Review & Free High Return Stock Watch Alerts - Улправда
Will Niagen Bioscience Inc. stock deliver shareholder valueJuly 2025 Highlights & Entry and Exit Point Strategies - Улправда
How strong is Niagen Bioscience Inc. stock balance sheetWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Investors in Niagen Bioscience (NASDAQ:NAGE) have seen incredible returns of 320% over the past three years - Yahoo Finance
Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates - MSN
Trade Recap: Is Niagen Bioscience Inc stock a smart buy before Fed meeting2025 Market Overview & Daily Market Momentum Tracking - moha.gov.vn
Niagen Bioscience Announces $10 Million Share Buyback - MSN
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How Niagen Bioscience Inc. (OCD1) stock reacts to fiscal policiesMarket Performance Report & Precise Buy Zone Tips - Newser
How Niagen Bioscience Inc. (OCD1) stock behaves under inflation pressureGold Moves & Low Risk High Reward Trade Ideas - Newser
A History of Outperforming Analyst Forecasts and Beating the Odds: Niagen Bioscience Inc (NAGE) - setenews.com
Can Niagen Bioscience Inc. (OCD1) stock sustain breakout momentumWeekly Trade Report & Capital Efficient Trading Techniques - Newser
Why Niagen Bioscience Inc. (OCD1) stock benefits from AI revolutionPortfolio Performance Report & Long-Term Growth Portfolio Plans - Newser
Is Niagen Bioscience Inc a good long term investmentTop Performing Stocks & Big Profit Small Budget - earlytimes.in
Taking the lead: Niagen Bioscience Inc (NAGE) - Setenews
A Look at Niagen Bioscience (NAGE) Valuation After New Skincare Launch and Long COVID Study Results - Sahm
Niagen Bioscience (NAGE): Evaluating Valuation After Long COVID Study and Tru Niagen Beauty Launch - Yahoo Finance
Niagen Bioscience launches beauty supplement - Drug Store News
Will Niagen Bioscience Inc. (OCD1) stock justify high valuationWatch List & Stepwise Trade Signal Guides - newser.com
Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):